In March 2024 Nykode Therapeutics announced “key updates” to the inverse vaccine platform with the potential to treat autoimmune diseases at a conference in the US. During the event, Nykode “demonstrated for the first time” a “significant effect” in a therapeutic setting in a preclinical model for Multiple Sclerosis (MS) with the inverse vaccine platform.
“Nykode Therapeutics’ technology platform rethinks conventional drug design through its intelligent modular design and tailored hyper targeting, tailored for the specific disease. The platform opens the door to unlimited possibilities and truly unique modalities within multiple therapeutic.”
The data shared at the conference also “illustrate the strong contribution” of the specific targeting unit and confirm that the disease protection is antigen-specific, which highlights the potential that the technology has in the autoimmune diseases field.
The next step in Nykode’s technology
Dr Agnete Fredriksen, Chief Business Officer and Co-founder of Nykode, commented that “demonstrating effect in a therapeutic setting has been the next important step for Nykode”.
“In addition to stopping the disease development, the data show that the disease protection is antigen-specific. This supports our technology’s potential to offer future treatments that precisely target specific autoimmune disorders without negatively affecting a fully functional immune system, a common side effect associated with today’s available treatments.”
The results bring “additional motivation” for Dr Fredriksen’s team to “pursue a completely new approach” to the treatment of autoimmune diseases. These “affect around every tenth person globally”, says Dr Fredriksen. In September 2023, Nykode announced that the inverse vaccine platform had prevented serious disease in MS and type 1 diabetes models in mice, which showcased the “broad disease-modifying potential in an antigen-specific manner”.
To participate in discussions about how vaccine technologies can revolutionise disease management do get your tickets to join us at the Congress in Washington this April or subscribe to our newsletters here!
